Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2024 16:45 ET | Source: Veru Inc.

Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders

MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
June 10, 2024 08:30 ET | Source: Veru Inc.

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
May 22, 2024 08:30 ET | Source: Veru Inc.

Veru to Present at the Jefferies Global Healthcare Conference

MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
May 15, 2024 08:30 ET | Source: Veru Inc.

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
May 14, 2024 08:30 ET | Source: Veru Inc.

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
May 08, 2024 06:30 ET | Source: Veru Inc.

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific...
May 02, 2024 08:30 ET | Source: Veru Inc.

Veru to Present at the GLP-1 Based Therapeutics Summit

MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
May 01, 2024 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
April 30, 2024 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30,...
April 25, 2024 08:30 ET | Source: Veru Inc.

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...